As Novo Nordisk and Pfizer fight over a promising GLP-1 pipeline at Metsera, Amgen is staying the course on its ...

Novo’s new offer would pay $62.20 per share in cash, revised from the earlier offer of $56.50, according to a Tuesday press ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

Due to the litigation Pfizer filed Friday and Monday against Metsera, Novo Nordisk and the biotech’s lead shareholder, CEO ...

Sarepta nevertheless plans to push for full FDA approval of Vyondys 53 and Amondys 45 based on what it said are “encouraging ...

Kygevvi is indicated for patients with thymidine kinase 2 deficiency whose symptoms arise by 12 years of age. The disease ...

Having seen Congress spend money to onshore semiconductor production, pharma groups are pushing for similar incentives for ...

Pfizer has filed two separate lawsuits in an effort to stop Novo Nordisk's unsolicited bid to acquire obesity biotech Metsera ...

Manifold will use its tissue-targeting shuttle technology to help Roche develop new therapeutics for diseases of the central ...

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...

Had Pfizer’s Freda Lewis-Hall not stepped in, SpringWorks' rare disease treatment may never have reached patients. Pharmas ...

Less than 24 hours after resigning his post as the FDA’s head drug regulator, George Tidmarsh is reportedly reconsidering his decision and vowing to fight for his name and credibility amid a probe ...